Previous 10 | Next 10 |
HOUSTON , April 11, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has entered into an agreement...
April 9, 2019 Palm Beach, FL – April 9, 2019 – In the last few years the number of clinical trials looking for new treatments for Leukemia (AML) has continued to grow. In 2017, a report from ManagedCare said that: “… There are over 400 phase 2 or phase 3 tri...
Moleculin Biotech (NASDAQ: MBRX ) has successfully expanded the clinical supply of Annamycin for its on-going clinical trials via BSP Pharmaceuticals S.p.A. in Latina, Italy. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
HOUSTON , April 9, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has successfully expanded the clinic...
HOUSTON , April 3, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that preclinical data supporting activi...
TORONTO , April 1, 2019 /PRNewswire/ -- CellCube Energy Storage Systems Inc. ("CellCube" or the "Company") (CSE CUBE) (CSE: CUBE.CN) (OTCQB: CECBF) ( Frankfurt 01X, WKN A2JMGP) on behalf of its wholly-owned subsidiary, EnerCube Switchgear Systems Inc. ("EnerCube") is ...
Thinly traded nano cap Moleculin Biotech ( MBRX -28.7% ) slumps on more than an 11x surge in volume in reaction to its public offering of 5.25M units at $1.00 per unit. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Moleculin Biotech (NASDAQ: MBRX ) -25% on announcing equity offering. More news on: Moleculin Biotech, Inc., DropCar, Inc., Fibrocell Science, Inc., Stocks on the move, Read more ...
HOUSTON , March 27, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the pricing of an underwritten public offer...
Moleculin Biotech launches a public offering of common stock. Price, volume and terms have yet to be announced. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial PR Newswire Based on an encouraging discussion in the End of Phase 1B /2 Meeting with FDA the Company plans to: Proceed with a pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) designed for po...
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML PR Newswire HOUSTON , July 10, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfoli...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...